Citigroup Maintains Sell on PTC Therapeutics, Raises Price Target to $26
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst David Lebowitz maintains a Sell rating on PTC Therapeutics (NASDAQ:PTCT) but raises the price target from $18 to $26.

May 21, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Citigroup analyst David Lebowitz maintains a Sell rating on PTC Therapeutics but raises the price target from $18 to $26.
The Sell rating suggests a negative outlook, but the raised price target indicates some positive reassessment of the company's value. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100